Traders Buy Gilead Sciences (GILD) on Weakness

Investors purchased shares of Gilead Sciences, Inc. (NASDAQ:GILD) on weakness during trading hours on Monday. $179.00 million flowed into the stock on the tick-up and $102.40 million flowed out of the stock on the tick-down, for a money net flow of $76.60 million into the stock. Of all equities tracked, Gilead Sciences had the 16th highest net in-flow for the day. Gilead Sciences traded down ($2.25) for the day and closed at $73.09

A number of equities analysts have recently weighed in on the company. Maxim Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and upped their target price for the company from $73.67 to $94.00 in a report on Thursday. Argus downgraded Gilead Sciences from a “buy” rating to a “hold” rating and upped their target price for the company from $73.25 to $73.77 in a report on Monday, November 13th. Mizuho upped their target price on Gilead Sciences from $77.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, November 8th. BMO Capital Markets dropped their target price on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating on the stock in a report on Friday, October 27th. Finally, J P Morgan Chase & Co set a $85.00 target price on Gilead Sciences and gave the company a “buy” rating in a report on Wednesday, October 25th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $85.22.

The firm has a market capitalization of $95,450.00, a price-to-earnings ratio of 7.86, a P/E/G ratio of -1.26 and a beta of 1.13. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating the consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. During the same quarter last year, the company posted $2.75 earnings per share. The company’s revenue for the quarter was down 13.2% compared to the same quarter last year. analysts forecast that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be issued a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $2.08 annualized dividend and a yield of 2.85%. Gilead Sciences’s dividend payout ratio (DPR) is presently 23.66%.

In other Gilead Sciences news, insider John F. Milligan sold 220,000 shares of the stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $72.88, for a total transaction of $16,033,600.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Robin L. Washington sold 51,820 shares of the stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total value of $4,404,700.00. Following the transaction, the chief financial officer now owns 43,352 shares in the company, valued at approximately $3,684,920. The disclosure for this sale can be found here. In the last quarter, insiders have sold 458,486 shares of company stock worth $35,190,731. Corporate insiders own 1.30% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. Keel Point LLC boosted its position in shares of Gilead Sciences by 0.4% in the first quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 11 shares during the period. Paradigm Financial Advisors LLC boosted its position in shares of Gilead Sciences by 0.3% in the second quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock valued at $617,000 after acquiring an additional 26 shares during the period. West Oak Capital LLC boosted its position in shares of Gilead Sciences by 0.7% in the second quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock valued at $330,000 after acquiring an additional 32 shares during the period. First Heartland Consultants Inc. boosted its position in shares of Gilead Sciences by 0.4% in the second quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock valued at $632,000 after acquiring an additional 39 shares during the period. Finally, Princeton Portfolio Strategies Group LLC boosted its position in shares of Gilead Sciences by 0.4% in the second quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock valued at $691,000 after acquiring an additional 41 shares during the period. Institutional investors own 76.23% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.com-unik.info/2017/12/04/traders-buy-gilead-sciences-gild-on-weakness.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

What are top analysts saying about Gilead Sciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Gilead Sciences Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit